82152 Martinsried, de
+49 (89) 8565-1600
AVONTEC announce results of a multiple dose clinical proof of concept study with its drug candidate AVT-01 decoy ODN in asthmatic patientsMartinsried/Munich, )
AVONTEC s multiple dose phase IIa study was a once daily treatment of AVT-01 on seven consecutive days. The study population comprised 33 male moderate asthmatics treated with AVT-01 decoy ODN and 15 male moderate asthmatics treated with placebo. The study was conducted in two Romanian and one English centers. Primary clinical endpoint was the reduction of bronchial hyperresponsiveness after methacholine challenge measured as the calculated PC20 difference between day 7 and day 0. Secondary efficacy endpoint was the reduction of bronchial hyperresponsiveness after methacholine challenge on treatment day 3.
While there was a trend, yet not a significant difference on day 3 between the AVT-01 decoy ODN and the placebo group, this difference was diminished on day 7 due to an unusually high effect on day 7 in the placebo group. Furthermore, there was an unusual high standard deviation of the primary efficacy criterion, which profoundly reduced the power of this multiple dose phase IIa study. Therefore, the chance to detect a real treatment effect was substantially reduced in this study.
Dr. Thomas Schulze, CEO of AVONTEC commented: "The results of this study are clearly disappointing. The study showed an exceptionally high variability of the primary efficacy criterion leading to a profound reduction of the statistical power. Therefore, we cannot conclude whether the treatment with AVT-01 decoy ODN was effective or not. However, the analysis of the complete data set helps us to further shape and follow through our clinical asthma development program."
About AVT-01 decoy ODN
AVT-01 decoy ODN contains a short, double-stranded oligonucleotide "decoy" that effectively inhibits STAT-1, a transcription factor shown to be strongly involved in the regulation of chronic inflammation. AVT-01 decoy ODN reduced inflammation in numerous pharmacological animal models. In pilot clinical studies this drug candidate showed an excellent safety profile and had demonstrable effects on relevant endpoints. Single doses of AVT-01 decoy ODN attenuated bronchial hyperresponsiveness in humans in a pilot clinical trial in asthmatic patients.
Asthma, one of the most common diseases in developed countries, is an inflammatory disease of the conducting airways characterized by bronchial edema, bronchial hyperresponsiveness and reversible airway obstruction. In mild to moderate disease, standard therapies such as short-acting beta-agonists and topical or systemic corticosteroids are very effective. However, in severe asthma, which affects only five to ten per cent of the asthma population but accounts for up to 50 per cent of the total treatment costs, inflammation and clinical symptoms are under poor control. Patients suffering from severe asthma have the highest morbidity and mortality, indicating an important unmet medical need.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.